57results about How to "Inhibition of disease progression" patented technology

A process for producing an antibody enzyme which involves an antibody structure analysis step of confirming the presence of a catalyst triplet residue structure wherein a serine residue, an aspartate residue and a histidine residue or a glutamate residue are located stereostructurally close to each other in the stereostructure of an antibldy anticipated based on its amino acid sequence. Since the above-described catalyst triplet residue structure is a structure specific to an antibody enzyme, an antibody enzyme can be efficiently screened by using the same. Examples of the antibody enzyme as described above include an antibody enzyme against Helicobacter pylori urease and an antibody enzyme against chemokine receptor CCR-5.

The invention belongs to the field of medical chemistry, relates to a novel pyridazinone BTK inhibitor as well as preparation and application thereof, in particular to a pyridazinone BTK inhibitor, apreparation method thereof, a pharmaceutical composition containing the same, and application thereof to treatment of Bruton's tyrosine kinase-related diseases.

The invention relates to the field of medicinal chemistry, relates to pyridazinone BTK inhibitors and an application thereof, and concretely relates to pyridazinone BTK inhibitors represented by formula (I), a preparation method thereof, a medicinal composition containing the compounds, and a use of the compounds or the medicinal composition in the treatment of Bruton's tyrosine kinase-related diseases.

The invention provides polypeptides encoded by open reading frames present in the genome of Mycobacterium tuberculosis but absent from the genome of BCG and diagnostic and prophylactic methodologies using these polypeptides.

The present invention relates to one kind of composite beverage and its preparation process. The composite beverage is prepared with wolfberry fruit, chrysanthemum, cassia seed, mulberry leaf and haw in certain weight proportion. It has the health functions of clearing away liver-fire to treat eye diseases, dispelling wind and heat, invigorating kidney and benefiting qi, and possesses obvious effect of treating eye fatigue, blurring eyesight, myopia, etc. The health beverage has no side effect.

Disclosed are: a method for detecting (diagnosing) visceral obesity in a subject; a test agent useful for the method; a method for searching for a substance that can be used as an active ingredient for ameliorating visceral obesity; and an ameliorating agent for visceral obesity or a medicinal agent for preventing a metabolic disease developed as a result of the progression of visceral obesity. As the test agent, a polynucleotide which comprises at least 15 nucleotides and can hybridize with a nucleotide sequence for coiled-coil domain containing protein 3 (CCDC3) gene or a nucleotide sequence complementary to the nucleotide sequence under stringent conditions or an antibody capable of recognizing CCDC3 protein is used.

The invention provides mycobacterium tuberculosis polypeptides and genes encoding them for use in diagnostic and prophylactic methodologies.

The invention relates to an oral liquid for relieving cough, treating asthma and detoxicating, which is prepared mainly from mulberry leaf, apricot seeds and white sugar. The oral liquid can be used for treating wind-heat type chronic bronchitis, or used as health food.

Methods and pharmaceutical compositions for preventing and/or treating acute and chronic inflammation and autoimmune diseases are provided herein. Tumor necrosis factor-α (TNFα) promotes an inflammatory response, which causes clinical problems associated with inflammation and autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma. TNFα is also implicated in promoting pathogenesis of diabetic retinopathy leading to loss of retinal microvascular cells. Methods herein contain the step of administering a prophylactic and/or therapeutic formulation of a pharmaceutical composition containing a recombinant soluble human TNF receptor or portions thereof which are TNFα inhibitors. These pharmaceutic compositions have been modified by conjugating natural amino acids such as proline and alanine, and/or serine (PA/S) via PASylation® to create a linear polypeptide that possesses fewer of the processing, preparation, formulation, cost, and other long-term issues of administering PEGylated drugs.

The invention relates to a medicinal composition containing C21-C28 fatty alcohols and non-steroidal anti-inflammatory medicaments, which is applicable to the treatment of herpesvirus infection, particularly the recurrent simplex herpesvirus infection of skin or mucous membranes.

The invention discloses a primer and a kit for detecting the susceptibility of paranoia schizophrenia. A method for detecting susceptibility genes of the paranoia schizophrenia relates to the detection the nucleotide sequence of a susceptibility gene GNB1L and particularly relates to an application of the primer and kit by virtue of detection of a polymorphic site rs748806 of the gene sequence of the susceptibility gene GNB1L in early evaluation of the paranoia schizophrenia. By virtue of the primer and the kit, the susceptibility gene of the paranoia schizophrenia can be accurately detected, and a new thought is provided for the deep research, the auxiliary diagnosis, the prevention, the treatment and the new drug research and development of the paranoia schizophrenia.

The invention provides a module for filling and supporting a femoral head necrosis area and a manufacturing method thereof. The module comprises a module body, the module body is a metal product whichis the same as or similar to a femoral head necrosis area of a patient in shape, bone ingrowth can be generated on the surface of the module body, the module body is of a hollow structure and is filled with a bone grafting material, the bone grafting material is autologous or allogenic or an artificial bone grafting material, and holes are formed in the surface of the module body, so that the module body can be in a sieve mesh shape or a honeycomb shape. The invention solves the problems that an existing femoral head necrosis early-stage and middle-stage supporting method is unreasonable, anexisting supporting structure has an inherent structure and is not matched with a femoral head necrosis area in form, consequently, the supporting local area is insufficient, the strength is inconsistent, part of the necrosis area cannot be effectively supported, and the treatment effect is affected. The invention belongs to the technical field of femoral head repair.

The invention discloses application of multilineage differentiation and sustained stress cells in preparation of anti-inflammatory drugs. The multilineage differentiation and sustained stress cells can be obtained from multiple kinds of mesenchymal tissue, including bone marrow, fat, umbilical cord, dermis and the like. Studies of the invention show that the multilineage differentiation and sustained stress cells are capable of effectively treating multiple kinds of inflammation, such as various diseases and symptoms including arthritis, tendinitis, rhinitis, pneumonia, nephritis, colitis, gynecological inflammation, prostatitis, cellulitis, ulcer, urticaria, tuberculosis, typhoid, autoimmune diseases (such as spondylitis, lupus erythematosus, lymphocytic thyroiditis and the like); and moreover, the multilineage differentiation and sustained stress cells are long in acting time, and have very high clinical application values.

The invention belongs to the technical field of traditional Chinese medicines, and discloses an ointment for treating rheumatoid arthritis. The ointment is prepared from the following raw materials: carthamus tinctorius, herba epimedii, cassia twigs, caulis spatholobi, fructus psoraleae, frankincense, myrrh, tuberculate speranskia herb, lycopodium clavatum, eucommia, radix aconiti preparata, rhizoma atractylodis, himalayan teasel roots, pericarpium arecae, salvia miltiorrhiza, pollen typhae, hawthorn fruits, cortex albizziae, rhizoma corydalis, rhizoma drynariae, radix angelicae pubescentis, dandelion, poria cocos, centipedes and scorpions. The ointment can treat both symptoms and root causes of rheumatoid arthritis, and is low in toxic and side effects and low in cost.

The application relates to a fusion protein comprising an antibody molecule, or antigen-binding fragment thereof, and a member of the vascular endothelial growth factor family, such as VEGF-C or VEGF-D. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ED-A isoform of fibronectin. In particular, the application relates to the therapeutic use of such fusion protein in the treatment of an inflammatory disease or disorder.

The invention relates to an Inula nervosa Wall oil capsule preparation, which is prepared from the following raw materials in parts by weight: 80 parts of Inula nervosa Wall, 25 parts of rhizoma anemarrhenae, 25 parts of costus root, 22 parts of curcuma aromatic, 20 parts of myrrh, 20 parts of prepared rehmannia root, 20 parts of tuckahoe, 18 parts of cortex albiziae, 18 parts of dandelion, 17 parts of rhizoma zingiberis, 15 parts of cistanche, 15 parts of cassia twig, 13 parts of root of common peony, 12 parts of rhizoma atractylodis, 12 parts of ligusticum wallichii, 10 parts of nux vomica, 10 parts of malt, 10 parts of radix aconiti preparata, 9 parts of peach kernel, 7 parts of liquorice, 7 parts of the seed of cowherb, 5 parts of teasel root and 5 parts of frankincense. The Inula nervosa Wall oil capsule preparation can treat both symptoms and root causes of rheumatoid arthritis, is harmless and non-toxic for a human body, does not have a side effect, has low price, is simple and convenient to prepare, and has a wide application prospect.

The invention provides a paclitaxel and fluoropyridazine BTK (Bruton 's tyrosine kinase) inhibitor combined pharmaceutical composition, characterized by comprising: an active ingredient and a pharmaceutically acceptable excipient, wherein the active ingredient is composed of paclitaxel and a BTK inhibitor represented by the formula (I); the mole ratio of the paclitaxel to the BTK inhibitor represented by the formula (I) in the active ingredient is (0.14-0.20):1. The pharmaceutical composition can be used for preparing a medicament for preventing and/or treating a disease associated with Bruton's tyrosine kinase, and the therapeutic effect is good.

The invention provides a taxol and novel nitrophthalazinone BTK inhibitor combined pharmaceutical composition, which consists of an active ingredient and pharmaceutically acceptable adjuvants, whereinthe active ingredient is composed of taxol and a BTK inhibitor shown as formula (I) (as shown in Description); and the mole ratio of the taxol to the BTK inhibitor shown as formula (I) in the activeingredient is at (0.14-0.20) to 1. The pharmaceutical composition can be used for preparing medicines for preventing and/or treating diseases related to Bruton's tyrosine kinase, with a good therapeutic effect.

The invention provides a paclitaxel and novel methoxyphthalazinone BTK (Bruton's Tyrosine Kinase) inhibitor combined medicinal composition. The composition comprises active ingredients and pharmaceutically acceptable auxiliary materials; the active ingredients consist of paclitaxel and a BTK inhibitor as shown in the formula (I); and the paclitaxel and the BTK inhibitor as shown in the formula (I)of the active ingredients are in the molar ratio of (0.14 to 0.20) to 1. The medicinal composition can be used for preparing a medicament for preventing and/or treating BTK-related diseases; and thetreatment effect is good.

The invention provides a medicine composition using taxol and a p-phenylphthalazinone type BTK inhibitor in a combined way. The medicine composition contains active ingredients and pharmaceutically acceptable auxiliary materials. The active ingredients is prepared from taxol and BTK inhibitors as shown in a formula (I) according to the mol ratio of (0.14 to 0.20):1. The medicine composition can beused for preparing medicine for preventing and/or treating diseases relevant to Bruton's tyrosine kinase; the treatment effect is good. The formula (I) is as shown in the description.

The invention relates to detection of a NOD1 gene single nucleotide polymorphism site rs2075820 in a patient suffering from a H.pylori infection-correlated disease, in particular to an amplification primer for detecting NOD1 gene single nucleotide polymorphism with a HRM detection technology and a detection method. The method has the advantages of easiness and convenience in operation, high detection speed, high flux, low cost, high sensitivity, high specificity, high repeatability and convenience in interpretation of results. The method facilitates the early detection, early diagnosis and early treatment of clinical H.pylori infection-correlated diseases, and has important significance to the immediate intervention and treatment for avoiding disease progression, adjustment of treatment scheme, prognostic prediction and prevention of clinical relapse.